Skip to main content

Table 1 The key reported clinical trials of of PD-1/PD-L inhibitors in patients with esophageal cancer

From: PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Tumor type Target Drug Phase and identification Sample size Clinical end point TRAEs Reference
EC PD-1 Nivolumab Phase II
JapicCTI-142422
64 ORR 17% (central assessment), 22% (investigator assessment); DCR 42% (central assessment), 53% (investigator assessment) All grade 60%, including diarrhea, decreased appetite, lung infection, rash, fatigue; grade ≥3 17%, including decreased appetite, lung infection, blood creatinine phosphokinase increased, dehydration Lancet Oncology 2017 [133]
EC PD-1 Nivolumab Phase II
JapicCTI-142422
64 ORR 17.2%; SD 25.0%; median OS 12.1 m Drug-related serious AEs 13.8%, including lung infection, dehydration, interstitial lung disease ASCO 2016 [29]
EC PD-1 Pembrolizumab Phase I
NCT02054806
23 ORR 30.4%; SD 13.0%; 6-month PFS rate 30.4%; 12-month PFS rate 21.7% All grade 39.1%, including decreased appetite; grade 3 26%, including decreased lymphocytes ASCO 2016 [28]
EC PD-1 Pembrolizumab Phase Ib
NCT02054806
23 ORR 23%; SD 18%; PD 59% All grade 26%; grade 3 9% ASCO 2015 [151]